Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?

Source Motley_fool

Key Points

  • Bristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker.

  • The pharma giant has a long history of successfully developing and marketing new drugs.

  • Bristol Myers Squibb is facing a major patent expiration, but its portfolio of newer drugs is performing well.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

Bristol Myers Squibb (NYSE:BMY) is a large, well-respected pharmaceutical company. It traces its history back to the mid-1800s. Right now, the company's portfolio of newer drugs, which it calls its "growth portfolio", just generated nearly $7.7 billion in revenue in a single quarter. That's a 12% increase over the same quarter in 2025. But is the stock worth buying? The risk/reward balance looks tilted toward reward for all but the most conservative investors. Here's why.

Bristol Myers Squibb's value proposition

The success Bristol Myers Squibb is having with its growth portfolio clearly indicates that this pharmaceutical giant hasn't lost its mojo. But investors are still downbeat on the stock (more on this below). So the dividend yield is a lofty 4.3%. The S&P 500 index (SNPINDEX:^GSPC) yields roughly 1.1%, the average healthcare stock yields 1.3%, and the average drug stock yields 1.3%. That above-market and industry yield will likely be very enticing to long-term dividend investors. Meanwhile, the roughly 55% dividend payout ratio leaves ample room for adversity and should mollify all but the most conservative income lovers.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Two researchers work in a laboratory.

Image source: Getty Images.

Notably, the dividend has been increased regularly, though not annually, for over three decades. There have been no dividend cuts along the way despite the company working through some difficult periods during that span. That shows the board of directors is strongly committed to returning value to shareholders through a reliable, slowly growing dividend. Adding to the allure is the fact that the stock's 13x price-to-earnings ratio is notably below the pharma industry average of roughly 28x. The high yield and relatively low P/E ratio will likely be of interest to value investors.

Growth investors will appreciate the above-highlighted success of the company's growth portfolio. That portfolio is a collection of over a dozen new drugs that, as of the third quarter, account for nearly 60% of the company's drug revenues. That's good news and bad news, however, and it highlights the risk that investors face if they decide to buy Bristol Myers Squibb.

Bristol Myers Squibb's big problem

The healthcare giant's legacy portfolio still accounts for around 40% of revenues, or roughly $5.4 billion. And one drug, Eliquis, is responsible for nearly $4.7 billion of that total. Eliquis is set to see generic competition as soon as 2028. When that happens, the revenue this drug produces will likely start to fall, and perhaps sharply. That is why investors remain downbeat on Bristol Myers Squibb's stock despite the success of its growth portfolio.

It is reasonable that extremely conservative investors might want to stay on the sidelines until after Eliquis' patent expires. However, it is important to remember that patent expirations are just a normal part of the pharmaceutical business. And given the success of the growth portfolio, Bristol Myers Squibb continues to execute well in new drug development. There's just a mismatch between when patents expire, which happens on a set schedule, and its development efforts, which do not happen on a set schedule.

In order to buy Bristol Myers Squibb, you need to believe it will get through this period. History suggests it will, and that's backed up by the success of the growth portfolio.

Most investors should consider taking this leap of faith

If you can't handle the uncertainty around the patent expiration of Eliquis, you shouldn't buy Bristol Myers Squibb. However, for most investors, including dividend, value, and perhaps even growth-focused types, the stock is probably worth a deep dive. The market doesn't appear to be giving the company enough credit for its success on the development front, and that is probably tilting the risk-reward scale toward reward.

Should you buy stock in Bristol Myers Squibb right now?

Before you buy stock in Bristol Myers Squibb, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $315,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $896,981!*

Now, it’s worth noting Stock Advisor’s total average return is 768% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 20, 2026.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
S&P 500 Breaks Critical Support: Is a Bigger Stock Market Crash Coming?The S&P 500 has fallen below one of Wall Street’s most closely watched warning levels, raising fears that the stock market correction could deepen.The index dropped to 7,323 on Tuesday, closing below
Author  Beincrypto
Nov 19, Thu
The S&P 500 has fallen below one of Wall Street’s most closely watched warning levels, raising fears that the stock market correction could deepen.The index dropped to 7,323 on Tuesday, closing below
placeholder
Is Tech in a Bear Market? 20 Tech Stocks Fall Up to 76% From HighsAll 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
Author  Beincrypto
23 hours ago
All 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
placeholder
Market News Today Australia: VIX Surges Nearly 16%, Gold Breaks US$3,600 and US Stocks SlideVIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
Author  Mitrade Team
22 hours ago
VIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
placeholder
Australia’s jobs market just cracked — has the AUD/USD rate story flipped?Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
Author  Mark Garro
21 hours ago
Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
placeholder
Gold Price Today: Can XAU/USD Hold $3,500? | Mitrade AUGold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
Author  Mitrade Team
17 hours ago
Gold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
goTop
quote